Toggle menu

PitSTOP

Start date:
August 2017
End date:
August 2018
Co-ordinated by:
Dr John Emelifeonwu and the EMERGE Team, RIE
Main trial site:
RIE

Primary Objective
To determine the prevalence of anterior pituitary gland dysfunction in traumatic brain injury in Scotland.

Secondary Objectives
To determine whether clinical and radiologically parameters available on presentation can predict likelihood of developing PTPD in patients with TBI.
To determine the optimal timing after TBI for blood tests to diagnose PTPD
To determine whether PTPD effects functional recovery as determined by the extended Glasgow Outcome Score (eGOS)

Chief Investigator

Dr John Emelifeonwu

Surgical Trainee, Clinical Neurosciences

Research Team

Mia Paderanga

Senior Research Nurse

Julia Grahamslaw

Lead Research Nurse

More EMERGE Trials

The Emergency Medicine Annotated Bioresource Consortium (EM-ABC): A pilot and feasability programme

Read more

EMERGE Biobank

Developing a bioresource for all emergency presentations

Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world

Read more

Garfield-VTE

Global Anticoagulant Registry In the FIELD – Venous Thromboembolic Events

The study with PP100-01 in combination with NAC is designed to determine safety and tolerability of PP100-01 when co-administered with NAC as compared to the 12-hr NAC treatment regime for patients that come to the hospital after an overdose of paracetamol/acetaminophen.

Read more

The POP Trial

A Randomised Open Label Exploratory, Safety and Tolerability Study with PP100-01 in Patients Treated with the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose